<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35435">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645266</url>
  </required_header>
  <id_info>
    <org_study_id>BHC-RD-SOP-038</org_study_id>
    <nct_id>NCT02645266</nct_id>
  </id_info>
  <brief_title>Mean Visual Acuity Changes Following Five Injections of Aflibercept</brief_title>
  <official_title>Mean Visual Acuity Changes Following Five Injections of Aflibercept and the Relationship Between Ocular and Serum Cytokine Levels and Mean Visual Acuity Gains in DME Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <brief_summary>
    <textblock>
      Diabetic Macular Edema is a serious ocular consequence of poorly controlled diabetes. Even
      though significant research has been done to clarify the pathogenesis of DME, a clear causal
      pathway of the complication is of yet undetermined. However, there is some consensus among
      researchers that a cascade of inflammatory markers plays an important role in the disease
      process. Here we hope to better delineate the role these inflammatory markers play by
      investigating whether basal levels predict response or lack thereof to Aflibercept.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine change in BCVA from baseline to month 5 of aflibercept treatment</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Visual Acuity Improvement With Aflibercept Injection</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving aflibercept 2.0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept</intervention_name>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Diagnosis of DME by a retina specialist 2. Age: 18 or older 3. VA between 25 and
             75 letters at baseline 4. Treatment na√Øve

        Exclusion Criteria:

          -  1. Unwilling to sign consent form 2. Previous anti-VEGF intravitreal treatment in
             affected eye 3. Actively taking systemic steroids 4. Ocular inflammatory disease or
             autoimmune disease 5. Previous laser treatment for DME within last 3 months (as
             wash-out period for laser treatment inflammation is approximately 3 months.

             6. Any ocular surgery within the last 3 months. 7. Previous retina surgery( PPV, ERM
             surgery etc) 8. Medically uncontrolled glaucoma 9. Any other retinal condition( CRAO,
             CRVO, wAMD, geographic atrophy) 10. Individuals with physical or mental disabilities
             that prevent accurate vision testing 11. Proliferative diabetic retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Varun Chaudhary, MD FRCSC</last_name>
    <phone>905-573-7777</phone>
    <phone_ext>38058</phone_ext>
    <email>vchaudh@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prima Moinul, MD</last_name>
    <phone>905-573-7777</phone>
    <phone_ext>38070</phone_ext>
    <email>prima.moinul@gmail.com</email>
  </overall_contact_backup>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 30, 2015</lastchanged_date>
  <firstreceived_date>December 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Varun Chaudhary</investigator_full_name>
    <investigator_title>Chief of Ophthalmology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
